The Navigator Company (NVG) Q3 2025 earnings summary

Executive summary

• Diversification into Tissue and Packaging offset subdued pulp and paper prices, now contributing 30–33% of EBITDA and strengthening resilience amid market volatility.

• Operational excellence and cost optimization led to significant reductions in cash costs across all segments, despite macroeconomic and geopolitical risks.

• Strategic acquisitions and integration, especially in the UK, boosted Tissue turnover by 17% YoY and expanded the product range and customer base.

• UWF sales volume reached a record high since 2022, with market share growing to 26% and best-ever quarter in Iberia.

• Revenue for the first nine months of 2025 was €1,489 million, down 5% YoY, with EBITDA at €300 million (margin 20.2%), and net income at €118 million, down 51%.

Financial highlights

• Turnover for the first nine months of 2025 reached €1,489 million, down 5% YoY.

• EBITDA was €300 million, down 30% YoY, with a margin of 20.2%.

• Net income fell 51% YoY to €118 million.

• Capex totaled €160 million, with 61% for sustainability and decarbonisation projects.

• Net debt to EBITDA ratio at 1.85x after significant CapEx and dividend payout.

Outlook and guidance

• Cautiously optimistic for short-term market developments, expecting improvement in Pulp, Tissue, and Packaging, while Printing and Writing Paper demand remains under pressure.

• Pulp prices in China and Europe are expected to rebound, with demand growth in both regions.

• Tissue demand projected to grow steadily, with further integration and efficiency gains in the UK.

• CapEx for ESG and decarbonization projects to remain elevated through 2026, then normalize to €100–120 million annually.

• Packaging segment to benefit from PM3 machine conversion, moving up to 4th in Europe for low-grammage flexible packaging.